SUNNYVALE, Calif., Oct. 17, 2018 /PRNewswire/ -- Building on its
heritage of patient-first innovation, at this year's ASTRO
(American Society for Radiation Oncology) Annual Meeting, Accuray
Incorporated (NASDAQ: ARAY) will showcase radiation therapy
solutions designed to enable clinicians to deliver truly
personalized cancer treatments aligned to the needs of each
patient. Meeting attendees can visit Accuray at booth #2511 on
October 21 - 23, 2018 in San Antonio, Texas to learn how advances in
Accuray radiation therapy delivery systems and software are making
it easier and faster to provide extremely precise results for the
full range of cancer cases, from initial treatment to adaptive
therapy to retreatments.
"We are proud to have the opportunity to attend this important
meeting and provide access to information, demonstrations and
educational opportunities for learning about advances in Accuray
technologies. We are committed to partnering with the radiation
oncology community to develop innovative products that will improve
patient care, now and into the future," said Lionel Hadjadjeba,
M.D., Senior Vice President, and Chief Commercial Officer at
Accuray.
Meeting Highlights
New products and upcoming developments
- CyberKnife® VOLO™ Optimizer: This
next-generation optimizer simplifies the process of creating
treatment plans, improves plan quality and enables more efficient
exploration of the tradeoffs between treatment time and plan
quality. Preliminary data from Accuray indicates that the
CyberKnife VOLO Optimizer will provide a significant reduction in
optimization time, and up to 50 percent reduction in treatment
delivery time. Accuray will be launching this new optimizer at its
booth at 11:00 am on Sunday, October
21st.
- CTrue™ IR (Iterative Reconstruction) for the
Radixact® System: This powerful IR software improves
soft-tissue contrast and reduces noise, enhancing image quality,
while maintaining the same low imaging dose and fast reconstruction
time as earlier versions of the software. These enhancements enable
clinicians to efficiently deliver precise treatments more quickly,
for more patients.
- Radixact System with Real-Time Motion Synchronization*
[510(k) pending, not available for sale]: Capabilities of the
Radixact System are being expanded to offer real-time motion
synchronization, with the goal of improving dose accuracy and
treatment times compared to other methods, such as gating. These
capabilities will build on the current Radixact System, which is
fully integrated with the Accuray Precision® Treatment
Planning System and iDMS™ Data Management System. These hardware
and software solutions work seamlessly together and were introduced
to help improve treatment outcomes and workflow efficiencies,
enabling clinicians to provide optimal treatments for more
patients, every day. *Not 510(k) cleared or available for
commercial distribution.
Events
Accuray will host two educational symposia and
a broad range of Accuray Exchange in Radiation Oncology (AERO™)
Academy sessions. ASTRO meeting attendees will have the chance to
learn from industry experts about clinical advances and best
practices that have the potential to improve cancer patients'
outcomes and quality of life.
Click here for more information or to register for the
symposia.
Symposia: Breast Cancer: Your Challenges Today – Our
Solutions for Tomorrow:
Sunday, October 21st from
12:15p.m. - 1:15p.m.
- Moderator: Jean-Philippe
Pignol, M.D., Ph.D. FRCPC; Dalhousie
University, Halifax,
Canada
- Panelists
-
- Asal Shoushtari Rahimi, M.D.,
MS; U.T. Southwestern Medical Center, Dallas,
TX, USA
- Nathan Corradini, MS, DABR
SSRMP; Clinica Luganese, Lugano, Switzerland
- Jennifer R. Bellon, M.D.;
Dana-Farber Cancer Institute, Boston,
MA, USA
- Carole Massabeau, M.D.; Institut Universitaire du Cancer de
Toulouse Oncopole, Toulouse,
France
Symposia: Dynamic Tracking and Motion Correction: Over 15
Years of Accuray Leadership:
Monday, October 22nd from
12:30p.m. - 1:30p.m.
- Moderator: Fabienne Hirigoyenberry-Lanson, Ph.D.,
Vice President Global Medical and Scientific Affairs,
Accuray
- Panelists
-
- Cristian Cotrutz, Ph.D.; Swedish Radiosurgery Center,
Seattle, WA, USA
- Jonathan W. Lischalk, M.D.;
Medstar Georgetown University Hospital,
Washington, DC, USA
- John Bayouth, Ph.D.;
University of Wisconsin School of
Medicine and Public Health, Madison, WI, USA
AERO™ Academy Sessions: October
21st – October 23rd
Attendees at this year's ASTRO meeting will have the opportunity to
participate in interactive discussions with clinical experts on the
use of Accuray technologies during daily presentations at Accuray
booth #2511. Topics include building a CyberKnife®
prostate SBRT practice; benefits of TomoDirect™ for breast cancer;
interactive planning on the CyberKnife System with the new VOLO™
Optimizer; demonstration of PreciseRTX™ Retreatment Option; and
plan adaptation with improved MVCT on the Radixact®
System.
Unique Hologram Technology
Throughout the ASTRO
meeting attendees will have the opportunity to view
viRTual—Where Art Meets Science, an immersive virtual
reality experience that provides an opportunity to see how Accuray
patient-first innovations are transforming what is possible for
cancer patients around the world.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative treatment
solutions that set the standard of care with the aim of helping
patients live longer, better lives. The company's leading-edge
technologies deliver the full range of radiation therapy and
radiosurgery treatments. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Safe Harbor
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences and outcomes, the
availability and effectiveness of new product enhancements and
releases, and Accuray's leadership position in radiation oncology
innovation and technologies. These forward-looking statements
involve risks and uncertainties. If any of these risks or
uncertainties materialize, or if any of the company's assumptions
prove incorrect, actual results could differ materially from the
results expressed or implied by these forward-looking statements.
These risks and uncertainties include, but are not limited to, the
company's ability to achieve widespread market acceptance of its
products, including new product offerings; the company's ability to
develop new products or enhance existing products to meet
customers' needs; delays in the development or release of new
offerings; the company's limited long-term clinical data supporting
the safety and efficacy of its products for certain users and such
other risks identified under the heading "Risk Factors" in the
company's annual report on Form 10-K, filed with the Securities and
Exchange Commission (the "SEC") on August
24, 2018 and as updated periodically with the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future
events. The company assumes no obligation to update
forward-looking statements to reflect actual performance or
results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent
required by applicable securities laws. Accordingly,
investors should not put undue reliance on any forward-looking
statements.
Media
Contacts:
|
|
Beth
Kaplan
|
Jayme
Maniatis
|
Public Relations
Director, Accuray
|
MSLGROUP
|
+1 (408)
789-4426
|
+1 (781)
684-6662
|
bkaplan@accuray.com
|
accuray@mslgroup.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/accuray-showcases-radiation-therapy-innovations-designed-to-improve-whats-possible-for-patients-at-astro-2018-300732492.html
SOURCE Accuray Incorporated